CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $15.1111.

Several brokerages have issued reports on CYRX. KeyCorp raised their price objective on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Needham & Company LLC lifted their target price on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Craig Hallum lifted their target price on shares of CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, June 3rd. Finally, Guggenheim lifted their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 5th.

CryoPort Stock Performance

Shares of CryoPort stock opened at $15.70 on Wednesday. CryoPort has a 1 year low of $6.69 and a 1 year high of $16.73. The company has a market capitalization of $791.28 million, a P/E ratio of 11.63 and a beta of 1.90. The company’s fifty day moving average is $13.79 and its two-hundred day moving average is $10.82.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. As a group, equities analysts expect that CryoPort will post -0.85 earnings per share for the current year.

Insider Activity

In other news, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $16.27, for a total value of $2,756,577.29. Following the sale, the chief financial officer owned 109,850 shares of the company’s stock, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ramkumar Mandalam sold 23,214 shares of CryoPort stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the sale, the director directly owned 67,894 shares in the company, valued at approximately $1,048,283.36. The trade was a 25.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 227,641 shares of company stock valued at $3,622,515 over the last quarter. Corporate insiders own 10.10% of the company’s stock.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently made changes to their positions in CYRX. UBS Group AG boosted its holdings in CryoPort by 6.8% during the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after buying an additional 90,363 shares in the last quarter. Mak Capital One LLC purchased a new stake in CryoPort during the third quarter worth about $7,756,000. Penbrook Management LLC boosted its holdings in CryoPort by 251.6% during the first quarter. Penbrook Management LLC now owns 185,775 shares of the company’s stock worth $1,538,000 after buying an additional 132,940 shares in the last quarter. First Eagle Investment Management LLC purchased a new stake in CryoPort during the fourth quarter worth about $2,996,000. Finally, Meros Investment Management LP boosted its holdings in CryoPort by 13.9% during the fourth quarter. Meros Investment Management LP now owns 626,427 shares of the company’s stock worth $6,014,000 after buying an additional 76,687 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.